ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CRIS Curis Inc

14.71
0.00 (0.00%)
Pre Market
Last Updated: 10:08:07
Delayed by 15 minutes
Share Name Share Symbol Market Type
Curis Inc NASDAQ:CRIS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 14.71 11.33 23.00 1 10:08:07

Curis to Release Second Quarter Financial Results and Hold Conference Call on August 2, 2018

27/07/2018 1:30pm

PR Newswire (US)


Curis (NASDAQ:CRIS)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Curis Charts.

LEXINGTON, Mass., July 27, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2018 financial results on Thursday, August 2, 2018, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT.

To access the live conference call, please dial (888) 346-6389 from the United States or 1 (412) 317-5252 from other locations, shortly before 8:30 a.m. EDT. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.

About Curis, Inc. 

Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the PDL1/VISTA antagonist CA-170, and the PDL1/TIM3 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.

Cision View original content:http://www.prnewswire.com/news-releases/curis-to-release-second-quarter-financial-results-and-hold-conference-call-on-august-2-2018-300687660.html

SOURCE Curis, Inc.

Copyright 2018 PR Newswire

1 Year Curis Chart

1 Year Curis Chart

1 Month Curis Chart

1 Month Curis Chart

Your Recent History

Delayed Upgrade Clock